A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.

<h4>Background</h4>The acute-phase increase in serum C-reactive protein (CRP) is used to diagnose and monitor infectious and inflammatory diseases. Little is known about the influence of genetics on acute-phase CRP, particularly in patients with chronic inflammation.<h4>Methods and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Benjamin Rhodes, Marilyn E Merriman, Andrew Harrison, Michael J Nissen, Malcolm Smith, Lisa Stamp, Sophia Steer, Tony R Merriman, Timothy J Vyse
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2010
Materias:
R
Acceso en línea:https://doaj.org/article/b8e95b426c724ace82a351f3a06758b0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:b8e95b426c724ace82a351f3a06758b0
record_format dspace
spelling oai:doaj.org-article:b8e95b426c724ace82a351f3a06758b02021-11-18T05:41:11ZA genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.1549-12771549-167610.1371/journal.pmed.1000341https://doaj.org/article/b8e95b426c724ace82a351f3a06758b02010-09-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20877716/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>The acute-phase increase in serum C-reactive protein (CRP) is used to diagnose and monitor infectious and inflammatory diseases. Little is known about the influence of genetics on acute-phase CRP, particularly in patients with chronic inflammation.<h4>Methods and findings</h4>We studied two independent sets of patients with chronic inflammation due to rheumatoid arthritis (total 695 patients). A tagSNP approach captured common variation at the CRP locus and the relationship between genotype and serum CRP was explored by linear modelling. Erythrocyte sedimentation rate (ESR) was incorporated as an independent marker of inflammation to adjust for the varying levels of inflammatory disease activity between patients. Common genetic variants at the CRP locus were associated with acute-phase serum CRP (for the most associated haplotype: p = 0.002, p<0.0005, p<0.0005 in patient sets 1, 2, and the combined sets, respectively), translating into an approximately 3.5-fold change in expected serum CRP concentrations between carriers of two common CRP haplotypes. For example, when ESR = 50 mm/h the expected geometric mean CRP (95% confidence interval) concentration was 43.1 mg/l (32.1-50.0) for haplotype 1 and 14.2 mg/l (9.5-23.2) for haplotype 4.<h4>Conclusions</h4>Our findings raise questions about the interpretation of acute-phase serum CRP. In particular, failure to take into account the potential for genetic effects may result in the inappropriate reassurance or suboptimal treatment of patients simply because they carry low-CRP-associated genetic variants. CRP is increasingly being incorporated into clinical algorithms to compare disease activity between patients and to predict future clinical events: our findings impact on the use of these algorithms. For example, where access to effective, but expensive, biological therapies in rheumatoid arthritis is rationed on the basis of a DAS28-CRP clinical activity score, then two patients with identical underlying disease severity could be given, or denied, treatment on the basis of CRP genotype alone. The accuracy and utility of these algorithms might be improved by using a genetically adjusted CRP measurement.Benjamin RhodesMarilyn E MerrimanAndrew HarrisonMichael J NissenMalcolm SmithLisa StampSophia SteerTony R MerrimanTimothy J VysePublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 7, Iss 9, p e1000341 (2010)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
spellingShingle Medicine
R
Benjamin Rhodes
Marilyn E Merriman
Andrew Harrison
Michael J Nissen
Malcolm Smith
Lisa Stamp
Sophia Steer
Tony R Merriman
Timothy J Vyse
A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.
description <h4>Background</h4>The acute-phase increase in serum C-reactive protein (CRP) is used to diagnose and monitor infectious and inflammatory diseases. Little is known about the influence of genetics on acute-phase CRP, particularly in patients with chronic inflammation.<h4>Methods and findings</h4>We studied two independent sets of patients with chronic inflammation due to rheumatoid arthritis (total 695 patients). A tagSNP approach captured common variation at the CRP locus and the relationship between genotype and serum CRP was explored by linear modelling. Erythrocyte sedimentation rate (ESR) was incorporated as an independent marker of inflammation to adjust for the varying levels of inflammatory disease activity between patients. Common genetic variants at the CRP locus were associated with acute-phase serum CRP (for the most associated haplotype: p = 0.002, p<0.0005, p<0.0005 in patient sets 1, 2, and the combined sets, respectively), translating into an approximately 3.5-fold change in expected serum CRP concentrations between carriers of two common CRP haplotypes. For example, when ESR = 50 mm/h the expected geometric mean CRP (95% confidence interval) concentration was 43.1 mg/l (32.1-50.0) for haplotype 1 and 14.2 mg/l (9.5-23.2) for haplotype 4.<h4>Conclusions</h4>Our findings raise questions about the interpretation of acute-phase serum CRP. In particular, failure to take into account the potential for genetic effects may result in the inappropriate reassurance or suboptimal treatment of patients simply because they carry low-CRP-associated genetic variants. CRP is increasingly being incorporated into clinical algorithms to compare disease activity between patients and to predict future clinical events: our findings impact on the use of these algorithms. For example, where access to effective, but expensive, biological therapies in rheumatoid arthritis is rationed on the basis of a DAS28-CRP clinical activity score, then two patients with identical underlying disease severity could be given, or denied, treatment on the basis of CRP genotype alone. The accuracy and utility of these algorithms might be improved by using a genetically adjusted CRP measurement.
format article
author Benjamin Rhodes
Marilyn E Merriman
Andrew Harrison
Michael J Nissen
Malcolm Smith
Lisa Stamp
Sophia Steer
Tony R Merriman
Timothy J Vyse
author_facet Benjamin Rhodes
Marilyn E Merriman
Andrew Harrison
Michael J Nissen
Malcolm Smith
Lisa Stamp
Sophia Steer
Tony R Merriman
Timothy J Vyse
author_sort Benjamin Rhodes
title A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.
title_short A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.
title_full A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.
title_fullStr A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.
title_full_unstemmed A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.
title_sort genetic association study of serum acute-phase c-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.
publisher Public Library of Science (PLoS)
publishDate 2010
url https://doaj.org/article/b8e95b426c724ace82a351f3a06758b0
work_keys_str_mv AT benjaminrhodes ageneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT marilynemerriman ageneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT andrewharrison ageneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT michaeljnissen ageneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT malcolmsmith ageneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT lisastamp ageneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT sophiasteer ageneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT tonyrmerriman ageneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT timothyjvyse ageneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT benjaminrhodes geneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT marilynemerriman geneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT andrewharrison geneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT michaeljnissen geneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT malcolmsmith geneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT lisastamp geneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT sophiasteer geneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT tonyrmerriman geneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
AT timothyjvyse geneticassociationstudyofserumacutephasecreactiveproteinlevelsinrheumatoidarthritisimplicationsforclinicalinterpretation
_version_ 1718424875336466432